The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
rene is working on a new therapy using stem cells. What it is working on looks promising, however like all other bio shares it is risky. You seem new to investing, so if you like bios, pick one or two shares do not put alot of money in them and have the patience to wait. Do not sell if the price moves down a bit, that is a sure way of losing money. GL
Oh please not also on this bb. That is one of the reasons inanaco fell out with me. I think that the " keys of the kingdom "is one big joke .
Do what he says and you will see that he can only talk about SCLP !! I do hold the share but I know that just like any other bio it might succeed or it might fail. Inanaco thinks that nothing can go wrong with his favourite share, a very dangerous thing when his views are taken over by those who are not into investing. He thinks that he knows all that there is to know about cancer and the saying... a little knowledge is a dangerous thing .. fits him perfectly.
Do you think that you know all the shares that I have in my portfolio ? Unlike some who are in SCLP and are happy to hold just one share, a very dangerous thing in my opinion ,I hold many shares. Howevert just because told you that I hold shares in SCLP do not run away with the idea that I am going to let you know the others . So do not try to guess or even give an opinion on what you " call my trading pattern " because you know nothing about it !!
I believe you were impressed with all the posting that went on yesterday evening.That is why you sold this morning,..... only my opinion and I might be wrong. However is a very good share and it will move up.
Sorry about your loss bios need time GL
I am in SCLP but I did not buy in because the company is going to be bought.no can really say that it will happen. SCLP is just another bio with a vaccine in clinical trial. It might succeed it might also fail.
This is from where the money for SLN will come two other milestones will prove pivotal to the company’s future. They relate to two Silence discovered entities that are licensed by Quark Pharmaceuticals, which are the focus of clinical trials being carried out by Pfizer and Novartis. The pair - PF655 (Pfizer) and QPI 1002 (Novartis) - could be worth US$13 million in milestone payments due in two tranches at the beginning and end of 2013 if they make the transition into phase III studies. Via Quark it has four of these arm’s length relationships with Pfizer and Novartis worth a potential US$170 million. None of this is remotely factored into a fully diluted market value of £38 million. The latest lifesaving inflow of cash was provided by a number of leading investors, including Robert Keith, who made his first fortune from games maker Eidos, creator of Lara Croft. Keith has 18 per cent of the company, while more than 50 per cent is held by investors very supportive of the current strategy, including Mortazavi and Evolution founder Richard Griffiths. They also have a successful track record of spotting backing winners.
read it again, this refers to Sirna not to SLN. Where did I say that SLN does not have a lead product > However, the top of the market was called in October 2006 when Merck agreed to pay US$1.1 billion for Sirna, a huge sum for a tiny company with nothing it could tangibly refer to as a commercial product
This is a big world and there are many bio companies out there. There is a place for both SLN and SCLP. This is the SLN board. You have now given out your knowledge, now let the scientist do theirs . I am sure they know what they are doing.
Could it be you are referring to this ? This RNA interference technology was based on Nobel Prize winning research, and it prompted a huge land-grab in this particular sector of medical science. However, the top of the market was called in October 2006 when Merck agreed to pay US$1.1 billion for Sirna, a huge sum for a tiny company with nothing it could tangibly refer to as a commercial product
SMALL CAPS FOCUS: Rosy future ahead for disease-eradicator Silence Therapeutics PUBLISHED:14:51 GMT, 1 October 2012| UPDATED: 15:00 GMT, 1 October 2012 Silence specialises in a method of allowing faulty genes to be controlled or shut down Quoted in the recent interim results statement, Silence Therapeutics director Ali Mortazavi was brutally honest when he admitted it had been a difficult six months for the biotech and its staff. A change of senior management and the write-down of the value of the key investment have drawn a line in the sand with the past. A successful £5.2 million fundraiser, completed in August, points to a far rosier future. Silence specialises in ‘gene silencing’ (hence the name) which allows faulty genes to be controlled or shut down. It copies the body's own method of fighting a virus. In theory, the process could be used to tackle cancers and other diseases that traditional chemistry and biotechnology failed to eradicate.e buy-to-let boom without buying property Up around 30 per cent in the past month, the share price suggests the market is slowly warming to the reformatted Silence story. The funding is key to the new strategy, as is the new management and supportive new investors. The cash injection gives the company two years’ breathing space – time enough to take its lead drug candidate, Atu027, through the clinical trial phases and along the value chain. The cancer treatment has just emerged from phase I trials on 33 patients with a clean bill of health. It is likely that Atu027 will be developed as an anti-metastatic, which would prevent or at least slow down the spread of secondary cancers Success in this endeavour would represent a huge breakthrough in the treatment of the disease and Silence has excellent pre-clinical data. In addition, the phase I trial has proven that Atu027 is extremely safe
Silence Therapeutics One such business is Silence Therapeutics, which is involved in pioneering drug therapies to help treat cancer, kidney disease and eye conditions that create blindness in the elderly. Although science has made great strides over recent decades, numerous diseases remain untreatable because no one has worked out how to enable the right drugs to target the right places in the body. It sounds simple but, in many cases, it is virtually impossible. At least, it has been until now. Silence has discovered a way of blocking messages from genes that tell cells in the body to make certain degenerative proteins, effectively 'silencing' the genes. This is known technically as RNA interference (RNAi). Silence is not the only company to be looking at this type of bio-technology – a couple of American groups are investigating it as well. But Silence describes itself as the tortoise in the hare and the tortoise race – it is moving more slowly than rivals but it expects ultimately to beat them. While American firms have been focusing on perfecting drugs in laboratory situations, Silence is taking a more practical approach, making sure that its treatments work in the lab but can also be administered effectively to people. Three of its drugs are undergoing clinical trials already and early signs are encouraging. The company is run by Ian Ross, a veteran of the biotech sector, who has held senior positions at pharmaceutical giants such as Sandoz and Roche, as well as Celltech in the UK, a company which was sold to the Belgian drugmaker UCB in 2004. Silence shares are trading at just under 20p, having suffered from the general malaise afflicting small, pioneering companies on Aim. But the stock was nearly 150p at the end of 2007. In fact, Astra Zeneca bought a 3% stake at 146p a share two years ago. Some shareholders may be aggrieved at the loss of value since but Astra Zeneca appears to be phlegmatic and is collaborating with Silence on various drug delivery methods. Silence is working with other pharmaceutical partners as well. It has long-standing arrangements with US groups Pfizer and Quark and only last week announced a partnership with the Japanese company Dainippon Sumitomo. The company has City supporters too – shareholders include Fidelity, Gartmore and Insight, as well as numerous individual investors.
Completion of the phase IIa study would take the company out to mid-2014. By that time two other milestones will have been passed that could be pivotal to the company’s future. They relate to two Silence discovered entities that are licensed by Quark Pharmaceuticals, which are the focus of clinical trials being carried out by Pfizer and Novartis. The pair - PF655 (Pfizer) and QPI 1002 (Novartis) - could be worth US$13 million in milestone payments due in two tranches at the beginning and end of 2013 if they make the transition into phase III studies. Via Quark it has four of these arm’s length relationships with Pfizer and Novartis worth a potential US$170 million
Shares in Silence Therapeutics (LON:SLN) jumped 11 per cent in afternoon trade after an American company working in the same technology field notched a stunning clinical success. working to cure cancer 03.10.12 Sarepta Therapeutics (NASDAQ:SRPT) shares doubled in value after trials revealed that its drug improved the walking ability of patients suffering a rare muscle wasting disease called Duchenne Muscular Dystrophy. Serapta’s innovations are RNA-based, which is a potentially breakthrough platform that has spawned a number of developments from the Silence stable
Please just ignore him. He can talk only about SCLP and what it is working on. These are two different bios they cannot be compared .
Wrong I was in the share not bought in after you wrote. Do not make me write that you just go overboard where SCLP is concerned. because you know that you do. It is enough reading all your " explanations and calculations " on the SCLP bb but do others on other bb have to read all your " information" also ?? Do you have to prove yourself on all boards ??
I just cannot understand why people come and post over on this bb things that have nothing to do with SLN. What SLN is working on is different, so it cannot be compared.
This is not the SCLP board. write what you want about your share on its bb!
We all know that you are not very good at spotting and that you only just started investing so ........